Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
BIOLOGICAL
2 trials
Sponsors
Sanofi Pasteur, a Sanofi Company
Conditions
Meningitis
Meningococcal Infections
Meningococcal Meningitis
Phase 2
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam
Completed
NCT02640404
Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Infections, Meningococcal Meningitis
Start: 2016-06-06
End: 2016-12-05
Updated: 2018-01-08
Phase 3
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Completed
NCT02842853
Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Infections, Meningococcal Meningitis
Start: 2016-07-15
End: 2017-02-28
Updated: 2022-04-05
Related Papers
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
Pediatric Research
2023-03-10
11 citations
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.
2020-06-19
25 citations
2723. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10–17 Years of Age
Open Forum Infectious Diseases
2019-10-01
3 citations
2719. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18–55 Years of Age
Open Forum Infectious Diseases
2019-10-01
2 citations